1.73  -0.17 (-8.95%)		06-12 16:00
Open: 1.9 High: 1.97 Volume: 2,098,760		Pre. Close: 1.9 Low: 1.71 Market Cap: 22(M)

Short term
Mid term
Targets	6-month :	3.69	1-year :	5.75
Resists	First :	3.16	Second :	4.92
Pivot price	2.43
Supports	First :	0.3	Second :	0.24
MAs	MA(5) :	1.92	MA(20) :	2.63
	MA(100) :	1.09	MA(250) :	1.32
MACD	MACD :	0.1	Signal :	0.2
%K %D	K(14,3) :	2.7	D(3) :	3.7
RSI	RSI(14): 44.4
52-week	High :	4.92	Low :	0.3

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ QUCY ] has closed above bottom band by 15.2%. Bollinger Bands are 93.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 21 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.98 - 2	2 - 2.01
Low:	1.67 - 1.7	1.7 - 1.71
Close:	1.7 - 1.74	1.74 - 1.76

Mainz Biomed N.V. is a specialized enterprise in the field of molecular genetics, primarily focused on cancer diagnostics. The company's core mission involves developing and producing market-ready molecular genetic diagnostic solutions specifically engineered for life-threatening medical conditions. Beyond creation, it actively engages in the global commercialization of its product portfolio, reaching markets across Europe, the United States, and other international territories. This firm was established on March 8, 2021, and maintains its headquarters in Mainz, Germany.

Wed, 29 Apr 2026
Quantum Cyber N.V. Announces Name Change, Major Investment, and Board Restructuring Following Shareholder Approval - Minichart

Tue, 28 Apr 2026
Quantum Cyber N.V. (QUCY) director files Form 3 showing zero share ownership - Stock Titan

Tue, 28 Apr 2026
David E. Lazar Secures CEO Role at Mainz Biomed N.V. with 97.4% Stake - TradingView

Tue, 28 Apr 2026
Quantum Cyber N.V. (QUCY) director discloses 2,000 Ordinary Shares on Form 3 - Stock Titan

Fri, 17 Apr 2026
QUCY Should I Buy - Intellectia AI

Thu, 26 Mar 2026
Mainz Biomed Receives Nasdaq Notice on Bid Price - The Globe and Mail

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	0 (M)
Shares Float	23 (M)
Held by Insiders	1.271e+007 (%)
Held by Institutions	8.1 (%)
Shares Short	685 (K)
Shares Short P.Month	0 (K)

EPS	-1.27e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-2 %
Return on Assets (ttm)	460.7 %
Return on Equity (ttm)	-94.3 %
Qtrly Rev. Growth	537080 %
Gross Profit (p.s.)	-76.52
Sales Per Share	-1135.63
EBITDA (p.s.)	906488
Qtrly Earnings Growth	-2.1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	0

Dividend	0
Forward Dividend	1.053e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.